On 9 August 2012, orphan designation (EU/3/12/1038) was granted by the European Commission to AOP Orphan Pharmaceuticals AG, Austria, for recombinant anti-CD3-bi-single-chain-Fv-diphtheria toxin fusion protein for the treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic / disseminated).

Key facts

Active substance
Recombinant anti-CD3-bi-single-chain-Fv-diphtheria toxin fusion protein
Disease / condition
Treatment of peripheral T-cell lymphoma (nodal, other extranodal and leukaemic / disseminated)
Date of decision
Orphan decision number

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

AOP Orphan Pharmaceuticals AG
Wilhelminenstrasse 91/IIf
A-1160 Vienna
Telephone: +43 1 503 72 44 10
Telefax: +43 1 503 72 44 61

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating